Renascience (4889) Reports Operating Loss of 82 Million Yen and Net Loss of 82 Million Yen

Renascience (4889) has released its latest financial results, reporting an operating loss of 82 million yen, an ordinary loss of 81 million yen, and a net loss of 82 million yen for the period. Basic earnings per share (EPS) stood at -5.95 yen.

From a financial structure perspective, the company maintains a robust equity ratio of 98.0% with zero interest-bearing debt (0.0 billion yen), reflecting a conservative and stable balance sheet. Meanwhile, retained earnings registered at -1.14 billion yen, with return on equity (ROE) at -11.98% and return on assets (ROA) at -11.21%. As an R&D-driven biotech venture currently in the investment phase toward future monetization, market participants will likely monitor the steady advancement of its clinical pipelines and strategic developments supported by its solid capital base.